6:44 PM
 | 
Dec 13, 2011
 |  BC Extra  |  Clinical News

Endocyte plummets on EC145 update

Endocyte Inc. (NASDAQ:ECYT) fell $6.72 (65%) to $3.57 on Tuesday after reporting data from an additional analysis of the open-label Phase II PRECEDENT trial of EC145 and providing an update on its regulatory plans for the platinum-resistant ovarian cancer product. Endocyte said a blinded independent review committee's analysis of PRECEDENT showed...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >